FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000210617> ?p ?o ?g. }

• W2000210617 abstract "You have accessJournal of UrologyKidney Cancer: Basic Research II1 Apr 2015MP47-06 BRCA1 ASSOCIATED PROTEIN-1 (BAP-1) LOSS IN CCRCC: MOLECULAR CORRELATIONS AND VALIDATION AS A PROGNOSTIC FACTOR. Nils Kroeger, Payal Kapur, Jiaoti Huang, Arie Belldegrun, James Brugarolas, and Allan Pantuck Nils KroegerNils Kroeger More articles by this author , Payal KapurPayal Kapur More articles by this author , Jiaoti HuangJiaoti Huang More articles by this author , Arie BelldegrunArie Belldegrun More articles by this author , James BrugarolasJames Brugarolas More articles by this author , and Allan PantuckAllan Pantuck More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1526AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES BAP1 is a classical two-hit tumor suppressor gene. It has been shown that BAP-1 is the only significantly mutated gene that is associated with poor prognosis in ccRCC. Yet, the reasons for this finding and interactions with central ccRCC pathways like the mTOR or VEGF pathways are largely unknown. Validation of existing prognostic and prediction molecular markers is one of the most important issues of biomarker research in ccRCC. Therefore, the current study sought to correlate BAP-1 loss with biologically relevant ccRCC pathways and to validate BAP-1 loss as prognostic factor in ccRCC. METHODS The study cohort was comprised of 321 ccRCC patients of whom 294 had evaluable tissue micro array (TMA) data. Patients with vs. without loss of BAP-1 expression were compared for differences in clinicopathological features, survival outcome and correlations with molecular markers of the mTOR, VEGF pathways as well as cell cycle markers. RESULTS Loss of BAP1 was found in 64 (21.8%) patients. Patients with vs. without BAP1 loss had significantly higher T stages (p<0.001), more often presented with distant metastases (p=0.017), and had larger tumors sizes (p=0.003) and more frequently sarcomatoid features (p=0.018). BAP1 loss was associated with worse survival outcome for both cancer specific (p <0.001) and recurrence free survival (p<0.001) in univariate analyses. However, when adjusted with parameters of the UISS, multivariable Cox regression analyses failed to retain BAP-1 loss as an independent predictor of either CSS (p=0.183) or RFS (p=0.233). Correlations with ccRCC biomarkers revealed lower expression of nuclear p27 (p=0.009) while phosphorylated-S6 was significantly higher (p<0.001) expressed in ccRCC with vs. without BAP-1 loss. Additionally, tumors without BAP-1 had greater VEGF-A (p=0.018), VEGF-R1 (p=0.001), and VEGF-R2 (p=0.016) expression. CONCLUSIONS The current investigation has validated an association of BAP-1 loss and poor prognosis in ccRCC. Immunohistochemistry can be used to rapidly and cost-effectively detect evidence of inactivating mutations in the BAP1 gene in paraffin-embedded ccRCC tissues. The interaction between BAP-1 and crucial mTOR and VEGF pathway members in BAP-1 negative ccRCC warrant further molecular investigation. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e554 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Nils Kroeger More articles by this author Payal Kapur More articles by this author Jiaoti Huang More articles by this author Arie Belldegrun More articles by this author James Brugarolas More articles by this author Allan Pantuck More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2000210617 created "2016-06-24" @default.
• W2000210617 creator A5013867374 @default.
• W2000210617 creator A5029912396 @default.
• W2000210617 creator A5039495553 @default.
• W2000210617 creator A5046541559 @default.
• W2000210617 creator A5069595062 @default.
• W2000210617 creator A5069683592 @default.
• W2000210617 date "2015-04-01" @default.
• W2000210617 modified "2023-09-23" @default.
• W2000210617 title "MP47-06 BRCA1 ASSOCIATED PROTEIN-1 (BAP-1) LOSS IN CCRCC: MOLECULAR CORRELATIONS AND VALIDATION AS A PROGNOSTIC FACTOR." @default.
• W2000210617 doi "https://doi.org/10.1016/j.juro.2015.02.1526" @default.
• W2000210617 hasPublicationYear "2015" @default.
• W2000210617 type Work @default.
• W2000210617 sameAs 2000210617 @default.
• W2000210617 citedByCount "0" @default.
• W2000210617 crossrefType "journal-article" @default.
• W2000210617 hasAuthorship W2000210617A5013867374 @default.
• W2000210617 hasAuthorship W2000210617A5029912396 @default.
• W2000210617 hasAuthorship W2000210617A5039495553 @default.
• W2000210617 hasAuthorship W2000210617A5046541559 @default.
• W2000210617 hasAuthorship W2000210617A5069595062 @default.
• W2000210617 hasAuthorship W2000210617A5069683592 @default.
• W2000210617 hasConcept C121608353 @default.
• W2000210617 hasConcept C126322002 @default.
• W2000210617 hasConcept C143998085 @default.
• W2000210617 hasConcept C2777472916 @default.
• W2000210617 hasConcept C2781197716 @default.
• W2000210617 hasConcept C2781278892 @default.
• W2000210617 hasConcept C37846818 @default.
• W2000210617 hasConcept C502942594 @default.
• W2000210617 hasConcept C54355233 @default.
• W2000210617 hasConcept C71924100 @default.
• W2000210617 hasConcept C86803240 @default.
• W2000210617 hasConceptScore W2000210617C121608353 @default.
• W2000210617 hasConceptScore W2000210617C126322002 @default.
• W2000210617 hasConceptScore W2000210617C143998085 @default.
• W2000210617 hasConceptScore W2000210617C2777472916 @default.
• W2000210617 hasConceptScore W2000210617C2781197716 @default.
• W2000210617 hasConceptScore W2000210617C2781278892 @default.
• W2000210617 hasConceptScore W2000210617C37846818 @default.
• W2000210617 hasConceptScore W2000210617C502942594 @default.
• W2000210617 hasConceptScore W2000210617C54355233 @default.
• W2000210617 hasConceptScore W2000210617C71924100 @default.
• W2000210617 hasConceptScore W2000210617C86803240 @default.
• W2000210617 hasIssue "4S" @default.
• W2000210617 hasLocation W20002106171 @default.
• W2000210617 hasOpenAccess W2000210617 @default.
• W2000210617 hasPrimaryLocation W20002106171 @default.
• W2000210617 hasRelatedWork W1994819973 @default.
• W2000210617 hasRelatedWork W2004612544 @default.
• W2000210617 hasRelatedWork W2019756490 @default.
• W2000210617 hasRelatedWork W2146920751 @default.
• W2000210617 hasRelatedWork W2898452673 @default.
• W2000210617 hasRelatedWork W2899245424 @default.
• W2000210617 hasRelatedWork W3098705614 @default.
• W2000210617 hasRelatedWork W4289731958 @default.
• W2000210617 hasRelatedWork W4297221372 @default.
• W2000210617 hasRelatedWork W4376526696 @default.
• W2000210617 hasVolume "193" @default.
• W2000210617 isParatext "false" @default.
• W2000210617 isRetracted "false" @default.
• W2000210617 magId "2000210617" @default.
• W2000210617 workType "article" @default.